Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Clara Gómez-Aleza"'
Autor:
Clara Gómez-Aleza, Bastien Nguyen, Guillermo Yoldi, Marina Ciscar, Alexandra Barranco, Enrique Hernández-Jiménez, Marion Maetens, Roberto Salgado, Maria Zafeiroglou, Pasquale Pellegrini, David Venet, Soizic Garaud, Eva M. Trinidad, Sandra Benítez, Peter Vuylsteke, Laura Polastro, Hans Wildiers, Philippe Simon, Geoffrey Lindeman, Denis Larsimont, Gert Van den Eynden, Chloé Velghe, Françoise Rothé, Karen Willard-Gallo, Stefan Michiels, Purificación Muñoz, Thierry Walzer, Lourdes Planelles, Josef Penninger, Hatem A. Azim, Sherene Loi, Martine Piccart, Christos Sotiriou, Eva González-Suárez
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
Receptor activator of nuclear factor-κB (RANK)/RANK-ligand (RANKL) signaling regulates the tumor-immune crosstalk. Here the authors show that systemic RANKL inhibition promotes CD8 + T cell infiltration in patients with early breast cancer and that
Externí odkaz:
https://doaj.org/article/25343e5b801f4662be448798ebe81a76
Autor:
Andrea Vethencourt, Eva M Trinidad, Anna Petit, María T Soler-Monsó, Clara Gómez Aleza, Ander Urruticochea, Amparo García-Tejedor, Anna Gumà Martinez, Veronica Obadia, Silvia Vazquez, Rafael Villanueva, Adela Fernánez, Monica Cejuela, Sabela Recalde Penabad, Agostina Stradella, Miguel Gil-Gil, Sonia Pernas, Eva Gonzalez-Suarez, Catalina Falo
Publikováno v:
Cancer Research. 82:P2-08
Background: Most breast cancers (BC) exhibit low immune infiltration and are unresponsive to immunotherapy. Inhibitors of the Receptor Activator of NFkB (RANK) pathway, such as denosumab, used for the treatment of bone metastasis, have been shown to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::347906a2aa7c8134ef274e70efcfb32a
https://doi.org/10.1158/1538-7445.sabcs21-p2-08-10
https://doi.org/10.1158/1538-7445.sabcs21-p2-08-10
Autor:
Thierry Walzer, Josef M. Penninger, Peter Vuylsteke, Gert Van den Eynden, Bastien Nguyen, Eva González-Suárez, Sherene Loi, Soizic Garaud, C. Velghe, David Venet, Françoise Rothé, Purificación Muñoz, Lourdes Planelles, Enrique Hernández-Jiménez, Philippe Simon, Hans Wildiers, Eva M. Trinidad, Sandra Benítez, Hatem A. Azim, Guillermo Yoldi, Christos Sotiriou, Roberto Salgado, Geoffrey J. Lindeman, Maria Zafeiroglou, Marina Ciscar, Alexandra Barranco, Stefan Michiels, Clara Gómez-Aleza, Martine Piccart, Laura Polastro, Karen Willard-Gallo, Pasquale Pellegrini, Marion Maetens, Denis Larsimont
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
Nature Communications
Nature communications, 11 (1
Repisalud
Instituto de Salud Carlos III (ISCIII)
Nature Communications
Nature communications, 11 (1
Repisalud
Instituto de Salud Carlos III (ISCIII)
Most breast cancers exhibit low immune infiltration and are unresponsive to immunotherapy. We hypothesized that inhibition of the receptor activator of nuclear factor-κB (RANK) signaling pathway may enhance immune activation. Here we report that los
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaab5273f7d1563d1814cb86c4091fe2
https://doaj.org/article/25343e5b801f4662be448798ebe81a76
https://doaj.org/article/25343e5b801f4662be448798ebe81a76
Autor:
Clara Gómez-Aleza, Alex Cordero, Sandra Benítez, Juliana C. Santos, Gonzalo Gómez-López, Ilaria De Benedictis, Jaime Redondo-Pedraza, Kevin Troulé, Alejandro Collado-Sole, Eva González-Suárez, Noelia Alcazar, Sabela Da Silva-Álvarez, Manuel Serrano, Guillermo Yoldi, Maria Jimenez, Ignacio Palmero, Ana S. Rocha, Manuel Collado, Adrián Sanz-Moreno, Patricia G. Santamaria
Publikováno v:
Dev. Cell 56, 1727-1741.e7 (2021)
Dipòsit Digital de la UB
Universidad de Barcelona
Developmental Cell
Digital.CSIC. Repositorio Institucional del CSIC
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Developmental Cell
Digital.CSIC. Repositorio Institucional del CSIC
instname
Summary Rank signaling enhances stemness in mouse and human mammary epithelial cells (MECs) and mediates mammary tumor initiation. Mammary tumors initiated by oncogenes or carcinogen exposure display high levels of Rank and Rank pathway inhibitors ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::926f73835f8b850ebdd5c7c20b9e7f71
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=62096
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=62096
RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer
Autor:
Marina Ciscar, Eva M Trinidad, Gema Perez‐Chacon, Mansour Alsaleem, Maria Jimenez, Maria J Jimenez‐Santos, Hector Perez‐Montoyo, Adrian Sanz‐Moreno, Andrea Vethencourt, Michael Toss, Anna Petit, Maria T Soler‐Monso, Victor Lopez, Jorge Gomez‐Miragaya, Clara Gomez‐Aleza, Lacey E Dobrolecki, Michael T Lewis, Alejandra Bruna, Silvana Mouron, Miguel Quintela‐Fandino, Fatima Al‐Shahrour, Antonio Martinez‐Aranda, Angels Sierra, Andrew R Green, Emad Rakha, Eva Gonzalez‐Suarez
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 4, Pp 1-12 (2023)
Abstract Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL p
Externí odkaz:
https://doaj.org/article/1a7e932a6a184ce6a384d4a58e43a0be
Autor:
Sander A. A. Kooijmans, Clara Gómez Aleza, Steve R. Roffler, Wouter W. van Solinge, Pieter Vader, Raymond M. Schiffelers
Publikováno v:
Journal of Extracellular Vesicles, Vol 5, Iss 0, Pp 1-11 (2016)
Background: Extracellular vesicles (EVs) are attractive candidate drug delivery systems due to their ability to functionally transport biological cargo to recipient cells. However, the apparent lack of target cell specificity of exogenously administe
Externí odkaz:
https://doaj.org/article/431db969517b4af0bab7bbe148130c46